Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial

BACKGROUND: The results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) suggested that approximately 70% of T1-2N0M0, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients can avoid chemotherapy and receive only adjuvant endo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Hong-Yu, Liu, Yin-Hua, Zhang, Hong, Zhang, Shuang, Xin, Ling, Xu, Ling, Ye, Jing-Ming, Li, Ting, Duan, Xue-Ning, Liu, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964955/
https://www.ncbi.nlm.nih.gov/pubmed/31809316
http://dx.doi.org/10.1097/CM9.0000000000000548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964955/
https://www.ncbi.nlm.nih.gov/pubmed/31809316
http://dx.doi.org/10.1097/CM9.0000000000000548

Ejemplares similares